Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151

Benzinga · 1d ago
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.